Germline Pathogenic Variants in DNA Repair Pathways: A Key Feature in a Significant Subset of Translocation-Associated Sarcomas

Strategic Insights -

A new study published in npj Precision Oncology has shed light on the incidence of germline pathogenic variants in DNA repair pathways in patients with translocation-associated sarcomas (TAS). The research, conducted by a team of scientists at the Memorial Sloan-Kettering Cancer Center, aimed to investigate the clinical impact of germline pathogenic/likely pathogenic (P/LP) variants in a diverse group of TAS patients. The study found that 28 patients (6.6%) carried Tier 1 germline P/LP variants, while 27 (6.3%) patients carried Tier 2 variants. The frequency of germline P/LP variants was lower among pediatric patients compared to older patients and differed across TAS histologies.

Key Takeaways:

  • The study found that germline pathogenic variants in DNA repair pathways are a key feature in a significant subset of translocation-associated sarcomas.
  • Tier 1 germline P/LP variants were more commonly found in patients of European ancestry and had a higher frequency of first- and second-degree relatives with cancer history.
  • In total, 46% of Tier 1 patients (n = 13) triggered significant interventions, including platinum-based chemotherapy and PARP inhibitors in two BRCA1/2 patients.
  • The study highlighted the incidence of clinically significant germline P/LP variants in TAS is lower in pediatric patients, questioning current sarcoma genetic screening guidelines.
  • Germline testing for all TAS patients is supported by the study.
  • The research found that all germline P/LP variants were monoallelic, dispersed across multiple genes, and enriched in DNA damage repair pathways.

Statistics:

  • 426 TAS patients with both tumor and germline DNA sequencing were investigated in the study.
  • 6.6% (28 patients) carried Tier 1 germline P/LP variants, while 6.3% (27 patients) carried Tier 2 variants.
  • 46% of Tier 1 patients (n = 13) triggered significant interventions, including platinum-based chemotherapy and PARP inhibitors in two BRCA1/2 patients.

Sources:

  • Germline pathogenic variants in DNA repair pathways: a key feature in a significant subset of translocation-associated sarcomas, npj Precision Oncology, 2025,9(1):1-10. (npj Precision Oncology - https://www.nature.com/npjprecisiononcology/).
  • NewsRx. Memorial Sloan-Kettering Cancer Center Researchers Describe Research in Precision Oncology (Germline pathogenic variants in DNA repair pathways: a key feature in a significant subset of translocation-associated sarcomas). Health & Medicine Week. May 30, 2025; p 2446.